One for all? Hitting multiple Alzheimer's disease targets with one drug

Frontiers in Neuroscience

Volumn 10, Issue APR, 2016, Pages

  Hughes, Rebecca E ^a   Nikolic, Katarina ^b   Ramsay, Rona R ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Alzheimer's Disease; Datamining; In silico; Multi target drugs; Rational drug design; Repurposing

Indexed keywords

ANTIDIABETIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; CLIOQUINOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONECOPRIDE; DONEPEZIL; GALANTAMINE; LIRAGLUTIDE; OXOISOAPORPHINE; RASAGILINE; RESVERATROL; RIVASTIGMINE; SELEGILINE; SEROTONIN ANTAGONIST; TACRINE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ACCESS TO INFORMATION; ALZHEIMER DISEASE; COMPUTER MODEL; DATA BASE; DATA MINING; DISEASE COURSE; DRUG DESIGN; DRUG INDICATION; DRUG SCREENING; DRUG TARGETING; HUMAN; NERVE CELL LESION; NONHUMAN; PARKINSON DISEASE; PHARMACOPHORE; SHORT SURVEY; SYMPTOM; TREATMENT RESPONSE;

EID: 84966377266     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2016.00177     Document Type: Short Survey

References (81)

1. Agis-Torres, A., Sölhuber, M., Fernandez, M., and Sanchez-Montero, J. M. (2014). Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for alzheimer's disease. Curr. Neuropharmacol. 12, 2-36. doi: 10.2174/1570159X113116660047.
2. Anand, R., Gill, K. D., and Mahdi, A. A. (2014). Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 76, 27-50. doi: 10.1016/j.neuropharm.2013.07.004.
3. Bar-Am, O., Yogev-Falach, M., Amit, T., Sagi, Y., and Youdim, M. B. H. (2004). Regulation of protein kinase C by the anti-parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem. 89, 1119-1125. doi: 10.1111/j.1471-4159.2004.02425.x.
4. Bartus, R. T., Dean, R. L. III, Beer, B., and Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-417. doi: 10.1126/science.7046051.
5. Bautista-Aguilera, O. M., Esteban, G., Bolea, I., Nikolic, K., Agbaba, D., Moraleda, I., et al. (2014a). Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 75, 82-95. doi: 10.1016/j.ejmech.2013.12.028.
6. Bautista-Aguilera, O. M., Samadi, A., Chioua, M., Nikolic, K., Filipic, S., Agbaba, D., et al. (2014b). N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual. J. Med. Chem. 57, 10455-10463. doi: 10.1021/jm501501a.
7. Boguski, M. S., Mandl, K. D., and Sukhatme, V. P. (2009). Repurposing with a difference. Science 324, 1394-1395. doi: 10.1126/science.1169920.
8. Bolea, I., Gella, A., Monjas, L., Perez, C., Rodriguez-Franco, M. I., Marco-Contelles, J., et al. (2013). Multipotent, permeable drug ASS234 inhibits A beta aggregation, possesses antioxidant properties and protects from A beta-induced apoptosis in vitro. Curr. Alzheimer Res. 10, 797-808. doi: 10.2174/15672050113109990151.
9. Bolea, I., Juarez-Jimenez, J., de los Rios, C., Chioua, M., Pouplana, R., Javier Luque, F., et al. (2011). Synthesis, biological evaluation, and molecular modeling of donepezil and N-(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl-N-methylprop-2-yn-1-ami ne hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 54, 8251-8270. doi: 10.1021/jm200853t.
10. Butler, M. M., Shinabarger, D. L., Citron, D. M., Kelly, C. P., Dvoskin, S., Wright, G. E., et al. (2012). MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic clostridium difficile. Antimicrob. Agents Chemother. 56, 4786-4792. doi: 10.1128/AAC.00508-12.
11. Carreiras, M. C., Mendes, E., Jesus Perry, M. J., Francisco, A. P., and Marco-Contelles, J. (2013). The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr. Top. Med. Chem. 13, 1745-1770. doi: 10.2174/15680266113139990135.
12. Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., et al. (2008). Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51, 347-372. doi: 10.1021/jm7009364.
13. Cho, S., and Hu, Y. (2007). Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp. Neurol. 203, 274-278. doi: 10.1016/j.expneurol.2006.07.021.
14. Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., et al. (2012). Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov. 11, 833-846. doi: 10.1038/nrd3869.
15. Corbett, A., Williams, G., and Ballard, C. (2013). Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals 6, 1304-1321. doi: 10.3390/ph6101304.
16. Couratier, P., Lesort, M., Sindou, P., Esclaire, F., Yardin, C., and Hugon, J. (1996). Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol. Chem. Neuropathol. 27, 259-273. doi: 10.1007/BF02815108.
17. Craft, S., Baker, L. D., Montine, T. J., Minoshima, S., Watson, G. S., Claxton, A., et al. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment a pilot clinical trial. Arch. Neurol. 69, 29-38. doi: 10.1001/archneurol.2011.233.
18. Deardorff, W. J., Feen, E., and Grossberg, G. T. (2015). The use of cholinesterase inhibitors across all stages of Alzheimer's disease. Drugs Aging 32, 537-547. doi: 10.1007/s40266-015-0273-x.
19. del Pino, J., Ramos, E., Bautista-Aguilera, O. M., Marco-Contelles, J., and Romero, A. (2014). Wnt signaling pathway, a potential target for Alzheimer's disease treatment, is activated by a novel multitarget compound ASS234. CNS Neurosci. Ther. 20, 568-570. doi: 10.1111/cns.12269.
20. East, S. P., and Silver, L. L. (2013). Multitarget ligands in antibacterial research: progress and opportunities. Expert Opin. Drug Discov. 8, 143-156. doi: 10.1517/17460441.2013.743991.
21. Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., et al. (2015). Targeting protein aggregation for the treatment of degenerative diseases. Nat. Rev. Drug Discov. 14, 759-780. doi: 10.1038/nrd4593.
22. Ekins, S., Mestres, J., and Testa, B. (2007a). In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br. J. Pharmacol. 152, 9-20. doi: 10.1038/sj.bjp.0707305.
23. Ekins, S., Mestres, J., and Testa, B. (2007b). In silico pharmacology for drug discovery: applications to targets and beyond. Br. J. Pharmacol. 152, 21-37. doi: 10.1038/sj.bjp.0707306.
24. Galdeano, C., Viayna, E., Sola, I., Formosa, X., Camps, P., Badia, A., et al. (2012). Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and Prion diseases. J. Med. Chem. 55, 661-669. doi: 10.1021/jm200840c.
25. Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., and Hoelscher, C. (2012). Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33, 265-276. doi: 10.1016/j.neurobiolaging.2010.02.014.
26. Hölscher, C. (2014). Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221, T31-T41. doi: 10.1530/JOE-13-0221.
27. Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690. doi: 10.1038/nchembio.118.
28. Hu, X., Fan, Q., Hou, H., and Yan, R. (2016). Neurological dysfunctions associated with altered BACE1-dependent neuregulin-1 signaling. J. Neurochem. 136, 234-249. doi: 10.1111/jnc.13395.
29. Hunter, K., and Hölscher, C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 13:33. doi: 10.1186/1471-2202-13-33.
30. Ji, H.-F., Li, X.-J., and Zhang, H.-Y. (2009). Natural products and drug discovery can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 10, 194-200. doi: 10.1038/embor.2009.12.
31. Kandalepas, P. C., and Vassar, R. (2014). The normal and pathologic roles of the Alzheimer's beta-secretase, BACE1. Curr. Alzheimer Res. 11, 441-449. doi: 10.2174/1567205011666140604122059.
32. Karran, E., Mercken, M., and De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698-U1600. doi: 10.1038/nrd3505.
33. Kim, T.-W. (2015). Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. Neurotherapeutics 12, 132-142. doi: 10.1007/s13311-014-0325-7.
34. Larson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., et al. (2012). The complex PrPc-Fyn couples human oligomeric A beta with pathological tau changes in Alzheimer's disease. J. Neurosci. 32, 16857. doi: 10.1523/JNEUROSCI.1858-12.2012.
35. Lecoutey, C., Hedou, D., Freret, T., Giannoni, P., Gaven, F., Since, M., et al. (2014). Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proc. Natl. Acad. Sci. U.S.A. 111, E3825-E3830. doi: 10.1073/pnas.1410315111.
36. Lezoualc'h, F. (2007). 5-HT4 receptor and Alzheimer's disease: the amyloid connection. Exp. Neurol. 205, 325-329. doi: 10.1016/j.expneurol.2007.02.001.
37. Li, S.-Y., Wang, X.-B., and Kong, L.-Y. (2014). Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease. Eur. J. Med. Chem. 71, 36-45. doi: 10.1016/j.ejmech.2013.10.068.
38. Licht, C. L., Knudsen, G. M., and Sharp, T. (2010). Effects of the 5-HT4 receptor agonist RS67333 and paroxetine on hippocampal extracellular 5-HT levels. Neurosci. Lett. 476, 58-61. doi: 10.1016/j.neulet.2010.04.002.
39. Lipton, S. A. (2006). Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5, 160-170. doi: 10.1038/nrd1958.
40. Liu, H., Wang, L., Lv, M., Pei, R., Li, P., Pei, Z., et al. (2014). AlzPlatform: an Alzheimer's disease domain-specific chemogenornics knowledgebase for polypharmacology and target identification research. J. Chem. Inf. Model. 54, 1050-1060. doi: 10.1021/ci500004h.
41. Loging, W., Rodriguez-Esteban, R., Hill, J., Freeman, T. B., and Miglietta, J. (2011). Cheminformatic/bioinformatic analysis of large corporate databases: application to drug repurposing. Drug Discov. Today Ther. Strateg. 8, 109-116. doi: 10.1016/j.ddstr.2011.06.004.
42. Lu, C., Guo, Y., Yan, J., Luo, Z., Luo, H.-B., Yan, M., et al. (2013a). Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. J. Med. Chem. 56, 5843-5859. doi: 10.1021/jm400567s.
43. Lu, C., Zhou, Q., Yan, J., Du, Z., Huang, L., and Li, X. (2013b). A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 62, 745-753. doi: 10.1016/j.ejmech.2013.01.039.
44. McClean, P. L., and Hölscher, C. (2014). Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76, 57-67. doi: 10.1016/j.neuropharm.2013.08.005.
45. McClean, P. L., Parthsarathy, V., Faivre, E., and Hölscher, C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594. doi: 10.1523/JNEUROSCI.0529-11.2011.
46. Mohamed, L. A., Qosa, H., and Kaddoumi, A. (2015). Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastignnine in rats. ACS Chem. Neurosci. 6, 725-736. doi: 10.1021/acschemneuro.5b00040.
47. Moloney, A. M., Griffin, R. J., Timmons, S., O'Connor, R., Ravid, R., and O'Neill, C. (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224-243. doi: 10.1016/j.neurobiolaging.2008.04.002.
48. Nygaard, H. B., van Dyck, C. H., and Strittmatter, S. M. (2014). Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimers Res. Ther. 6:8 doi: 10.1186/alzrt238.
49. Oldfield, E., and Feng, X. (2014). Resistance-resistant antibiotics. Trends Pharmacol. Sci. 35, 664-674. doi: 10.1016/j.tips.2014.10.007.
50. Ozer, E. O., Tan, O. U., Ozadali, K., Kucukkilinc, T., Balkan, A., and Ucar, G. (2013). Synthesis, molecular modeling and evaluation of novel N '-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and A beta aggregation. Bioorg. Med. Chem. Lett. 23, 440-443. doi: 10.1016/j.bmcl.2012.11.064.
51. Palmer, A. M. (2011). Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol. Sci. 32, 141-147. doi: 10.1016/j.tips.2010.12.007.
52. Pérez, V., Marco, J. L., Férnandez-Alvarez, E., and Unzeta, M. (1999). Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol. 127, 869-876. doi: 10.1038/sj.bjp.0702600.
53. Prati, F., Uliassi, E., and Bolognesi, M. L. (2014). Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases. MedChemComm 5, 853-861. doi: 10.1039/c4md00069b.
54. Rafii, M. S., Walsh, S., Little, J. T., Behan, K., Reynolds, B., Ward, C., et al. (2011). A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76, 1389-1394. doi: 10.1212/WNL.0b013e318216eb7b.
55. Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., et al. (2015). Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. J. Med. Chem. 58, 3172-3187. doi: 10.1021/acs.jmedchem.5b00115.
56. Rosini, M., Simoni, E., Bartolini, M., Tarozzi, A., Matera, R., Milelli, A., et al. (2011). Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. Eur. J. Med. Chem. 46, 5435-5442. doi: 10.1016/j.ejmech.2011.09.001.
57. Russo, O., Cachard-Chastel, M., Riviere, C., Giner, M., Soulier, J.-L., Berthouze, M., et al. (2009). Design, synthesis, and biological evaluation of new 5-HT(4) receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. J. Med. Chem. 52, 2214-2225. doi: 10.1021/jm801327q.
58. Samadi, A., de los Ríos, C., Bolea, I., Chioua, M., Iriepa, I., Moraleda, I., et al. (2012). Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. Med. Chem. 52, 251-262. doi: 10.1016/j.ejmech.2012.03.022.
59. Schrijvers, E. M. C., Witteman, J. C. M., Sijbrands, E. J. G., Hofman, A., Koudstaal, P. J., and Breteler, M. M. B. (2010). Insulin metabolism and the risk of Alzheimer disease the rotterdam study. Neurology 75, 1982-1987. doi: 10.1212/WNL.0b013e3181ffe4f6.
60. Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., et al. (2011). Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3:96ra77. doi: 10.1126/scitranslmed.3001318.
61. Steindl, T. M., Schuster, D., Laggner, C., and Langer, T. (2006). Parallel screening: A novel concept in pharmacophore modeling and virtual screening. J. Chem. Inf. Model. 46, 2146-2157. doi: 10.1021/ci6002043.
62. Stryjewski, M. E., Potgieter, P. D., Li, Y.-P., Barriere, S. L., Churukian, A., Kingsley, J., et al. (2012). TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 56, 5476-5483. doi: 10.1128/AAC.00712-12.
63. Tang, H., Zhao, L.-Z., Zhao, H.-T., Huang, S.-L., Zhong, S.-M., Qin, J.-K., et al. (2011). Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation inhibitors. Eur. J. Med. Chem. 46, 4970-4979. doi: 10.1016/j.ejmech.2011.08.002.
64. Tyagi, A., Gupta, S., Pandey, A., and Mohan, C. G. (2010). Alzheimer's disease multi-target directed inhibitor design using sequential virtual screening techniques. Curr. Res. Inf. Pharm. Sci. 11, 29-32. Available online at: http://www.niper.ac.in/29_crips.pdf.
65. Vassar, R. (2014). BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimer's Res. Ther. 6, 89-89. doi: 10.1186/s13195-014-0089-7.
66. Wang, L., Ma, C., Wipf, P., Liu, H., Su, W., and Xie, X.-Q. (2013). Target hunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. Aaps J. 15, 395-406. doi: 10.1208/s12248-012-9449-z.
67. Weinreb, O., Amit, T., Bar-Am, O., and Youdim, M. B. H. (2010). Rasagiline: a novel anti-parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 92, 330-344. doi: 10.1016/j.pneurobio.2010.06.008.
68. Wilkinson, D. G., Francis, P. T., Schwam, E., and Payne-Parrish, J. (2004). Cholinesterase inhibitors used in the treatment of Alzheimer's disease the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21, 453-478. doi: 10.2165/00002512-200421070-00004.
69. Wisniewski, T., and Goñi, F. (2014). Immunotherapy for Alzheimer's disease. Biochem. Pharmacol. 88, 499-507. doi: 10.1016/j.bcp.2013.12.020.
70. Xing, S.-H., Zhu, C.-X., Zhang, R., and An, L. (2014). Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evid. Based Complement. Alternat. Med. 2014, 363985-363985. doi: 10.1155/2014/363985.
71. Xu, S. S., Gao, Z. X., Zheng, W., Du, Z. M., Xu, W. A., Yang, J. S., et al. (1995). Efficacy of tablet huperzine-a on memory, cognition, and behavior in Alzheimers-disease. Acta Pharmacol. Sin. 16, 391-395.
72. Yogev-Falach, M., Amit, T., Bar-Am, O., and Youdim, M. B. H. (2003). The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J. 17, 2325. doi: 10.1096/fj.03-0078fje.
73. Youdim, M. B. H. (2006). The path from anti Parkinson drug selegiline and rasagiline to multi-functional neuroprotective anti Alzheimer drugs ladostigil and M30. Curr. Alzheimer Res. 3, 541-550. doi: 10.2174/156720506779025288.
74. Youdim, M. B. H. (2013). Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp. Neurobiol. 22, 1-10. doi: 10.5607/en.2013.22.1.1.
75. Youdim, M. B. H., Finberg, J. P. M., Levy, R., Sterling, J., Lerner, D., Berger-Paskin, T., et al. (1995). R-Enantiomers of N-Propargyl-Aminoindan Compounds, their Preparation and Pharmaceutical Compositions Containing Them. U.S. Patent No: US5457133 A.
76. Youdim, M. B. H., Gross, A., and Finberg, J. P. M. (2001). Rasagiline N-propargyl-1R(+)-aminoindan, a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132, 500-506. doi: 10.1038/sj.bjp.0703826.
77. Youdim, M. B. H., Maruyama, W., and Naoi, M. (2005). Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today 41, 369-391. doi: 10.1358/dot.2005.41.6.893613.
78. Zheng, H., Fridkin, M., and Youdim, M. (2014). From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals 7, 113-135. doi: 10.3390/ph7020113.
79. Zheng, H., Fridkin, M., and Youdim, M. B. H. (2010a). Site-activated chelators derived from anti-parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease. Neurochem. Res. 35, 2117-2123. doi: 10.1007/s11064-010-0293-1.
80. Zheng, H., Gal, S., Weiner, L. M., Bar-Am, O., Warshawsky, A., Fridkin, M., et al. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95, 68-78. doi: 10.1111/j.1471-4159.2005.03340.x.
81. Zheng, H., Youdim, M. B. H., and Fridkin, M. (2010b). Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem. Biol. 5, 603-610. doi: 10.1021/cb900264w.